<![CDATA[Exelixis, Inc. 보도자료 - 뉴스와이어]]>https://www.newswire.co.kr/?md=A10&act=article&no=28543>Thu, 14 May 2026 13:34:48 +0900Copyright (c) 2004~2026 Korea Newswire All rights reservedko-KR<![CDATA[Exelixis and Takeda Enter into Exclusive Licensing Agreement to Commercialize and Develop Novel Cancer Therapy Cabozantinib in Japan]]>https://www.newswire.co.kr/newsRead.php?no=844355Wed, 01 Feb 2017 10:55:00 +0900<![CDATA[엑셀릭시스, 새로운 암 치료제인 카보잔티닙을 일본서 상용화하기 위해 다케다제약과 독점 라이선싱 계약 체결]]>https://www.newswire.co.kr/newsRead.php?no=844356Wed, 01 Feb 2017 10:55:00 +0900